Research on primary aldosteronism and its effects on hypertension
Chongqing Primary Aldosteronism Study
This study is trying to understand how primary aldosteronism affects high blood pressure over time by looking at a large group of patients and collecting samples to find better ways to manage the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Chongqing Medical University Academic / other |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Trial ID | NCT03224312 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a large cohort of patients with primary aldosteronism (PA) and essential hypertension, focusing on long-term follow-up of cardiovascular and renal outcomes. It will collect extensive biological samples, including blood, urine, and adrenal tissue, to create a comprehensive database for genomics, metabonomics, and proteomics analysis. The goal is to explore the mechanisms behind PA, identify risk factors, and develop diagnostic methods and biomarkers for better management of the condition.
Who should consider this trial
Good fit: Ideal candidates for this study are hypertensive patients who have completed aldosterone-renin ratio screening and are willing to provide informed consent.
Not a fit: Patients with severe cardiac, hepatic, or renal dysfunction, or those with other types of secondary hypertension, will not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and management of primary aldosteronism, potentially reducing cardiovascular and renal complications in affected patients.
How similar studies have performed: While this study builds on existing research in hypertension, its specific focus on primary aldosteronism and comprehensive biological analysis may offer novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. hypertensive patients who completed ARR screening and necessary further tests; 2. Voluntary to sign the informed consent. Exclusion Criteria: 1. patients with severe cardiac, hepatic or renal dysfunction; 2. suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis et al.
Where this trial is running
Chongqing, Chongqing Municipality
- Qifu Li — Chongqing, Chongqing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Qifu Li, phD
- Email: liqifu@yeah.net
- Phone: +86 023-89011552
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.